Author:
Alhaja Maher,Chen Sherry,Chin Alan C,Schulte Brian,Legasto Carlo S
Publisher
Springer Science and Business Media LLC
Reference21 articles.
1. Cancer therapy-induced cardiac toxicity in early breast cancer: addressing the unresolved issues;Khouri MG;Circulation,2012
2. Liposome-encapsulated doxorubicin compared with conventional doxorubicin in a randomized multicenter trial as first-line therapy of metastatic breast carcinoma;Harris L;Cancer,2002
3. FDA. Adriamycin® (doxorubicin HCl injection) for intravenous use [prescribing information]. Pfizer Injectables. (2013). Accessed: July 4, 2023: https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/050467s078,050629s030lbl.pdf.
4. Reduced incidence of severe palmar-plantar erythrodysesthesia and mucositis in a prospective multicenter phase II trial with pegylated liposomal doxorubicin at 40 mg/m2 every 4 weeks in previously treated patients with metastatic breast cancer;Al-Batran SE;Oncology,2006
5. Baxter Healthcare Corporation. DOXIL® (doxorubicin HCl liposome injection) for intravenous use [prescribing information]. (2019). Accessed: August 8, 2022: https://www.baxterpi.com/pi-pdf/Doxil_Baxter_PI.pdf.